WO2026026827 - ANTI-IL-5 ANTIBODY FORMULATION AND PREPARATION METHOD THEREFOR
National phase entry is expected:
Publication Number
WO/2026/026827
Publication Date
05.02.2026
International Application No.
PCT/CN2025/111380
International Filing Date
30.07.2025
Title **
[English]
ANTI-IL-5 ANTIBODY FORMULATION AND PREPARATION METHOD THEREFOR
[French]
FORMULATION D'ANTICORPS ANTI-IL-5 ET SON PROCÉDÉ DE PRÉPARATION
[Chinese]
抗IL-5抗体制剂及其制备方法
Applicants **
BIO-THERA SOLUTIONS, LTD.
Inventors
ZHONG, Huizhen
LI, Yuanqiang
YU, Lei
WU, Yong
Priority Data
202411034490.7
30.07.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1894 | |
| EPO | Filing, Examination, Granting | 14643 | |
| Japan | Filing, Examination, Granting | 2340 | |
| South Korea | Filing, Examination, Granting | 2536 | |
| USA | Filing, Examination, Granting | 4940 |
Total:
26,353
Contact Us
Abstract[English]
Provided are an anti-IL-5 antibody lyophilized formulation and a reconstituted formulation thereof. The anti-IL-5 antibody lyophilized formulation comprises an anti-IL-5 antibody, a histidine buffer, sucrose, and polysorbate 80. The anti-IL-5 antibody lyophilized formulation has excellent stability, has a lower osmotic pressure after reconstitution, reduces injection pain for patients, and is more suitable for clinical use.[French]
L'invention concerne une formulation lyophilisée d'anticorps anti-IL-5 et une formulation reconstituée de celle-ci. La formulation lyophilisée d'anticorps anti-IL-5 comprend un anticorps anti-IL-5, un tampon d'histidine, du saccharose et du polysorbate 80. La formulation lyophilisée d'anticorps anti-IL-5 a une excellente stabilité, a une pression osmotique inférieure après reconstitution, réduit la douleur d'injection pour les patients, et est plus adaptée à un usage clinique.[Chinese]
提供抗IL-5抗体冻干制剂及其复溶制剂，包括抗IL-5抗体、组氨酸缓冲剂、蔗糖和聚山梨酯80。该抗IL-5抗体冻干制剂具有优越的稳定性，复溶后具有更低的渗透压，减轻患者注射疼痛，更适宜临床使用。